Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LAB
stocks logo

LAB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
18.50M
-60.4%
-0.025
-49.39%
18.60M
-54.41%
-0.015
-68.62%
20.53M
-5.65%
-0.010
-74.94%
Estimates Revision
The market is revising Downward the revenue expectations for Standard BioTools Inc. (LAB) for FY2025, with the revenue forecasts being adjusted by -6.83% over the past three months. During the same period, the stock price has changed by 10.77%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.76%
In Past 3 Month
Stock Price
Go Up
up Image
+10.77%
In Past 3 Month
Wall Street analysts forecast LAB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LAB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
Current: 1.440
sliders
Low
1.35
Averages
1.35
High
1.35
Current: 1.440
sliders
Low
1.35
Averages
1.35
High
1.35
TD Cowen
Hold
downgrade
2025-11-05
Reason
TD Cowen
Price Target
2025-11-05
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Standard BioTools to $1.35 from $1.55 and keeps a Hold rating on the shares. The firm said there were no surprises in the print with the company now reporting continuing operations revenue post the announced sale of SomaLogic.
TD Cowen
Buy
to
Hold
downgrade
2025-08-13
Reason
TD Cowen
Price Target
2025-08-13
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Standard BioTools to Hold from Buy with a price target of $1.55, down from $1.60, post the Q2 report. The company sees a lower growth outlook for the core business and less visibility following the sale of SomaLogic. The company's core business trends will continue to be challenged amid macro headwinds, the analyst tells investors in a research note.
Keybanc
Paul Knight
Buy
to
Hold
Downgrades
n/a
2025-02-27
Reason
Keybanc
Paul Knight
Price Target
n/a
2025-02-27
Downgrades
Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Standard BioTools Inc (LAB.O) is -26.18, compared to its 5-year average forward P/E of -10.39. For a more detailed relative valuation and DCF analysis to assess Standard BioTools Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.39
Current PE
-26.18
Overvalued PE
-0.32
Undervalued PE
-20.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.51
Undervalued EV/EBITDA
-12.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.84
Current PS
0.00
Overvalued PS
4.40
Undervalued PS
1.29
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

LAB News & Events

Events Timeline

(ET)
2025-08-11
16:13:04
Standard BioTools sees FY25 revenue $165M-$175M, consensus $169.13M
select
2025-08-11
16:12:17
Standard BioTools reports Q2 EPS (9c), consensus (4c)
select
2025-08-06 (ET)
2025-08-06
07:28:41
Standard BioTools, Precision Health, Singapore launch proteomic collaboration
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28Benzinga
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.

  • Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.

  • Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.

[object Object]
Preview
2.0
11-28NASDAQ.COM
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26

  • Biotech Stocks Surge: Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a lack of major news.

  • Modular Medical's Approval: Modular Medical, Inc. saw an 11.51% increase in share price after receiving Institutional Review Board approval for its Pivot insulin delivery system study, which aims to gather critical data on device usability.

  • Standard BioTools Collaboration: Standard BioTools Inc. advanced 4.90% following a strategic partnership announcement with Molecular Instruments to enhance protein imaging capabilities through next-generation Imaging Mass Cytometry workflows.

  • Ongoing Investor Optimism: Companies like Werewolf Therapeutics, Cogent Biosciences, and Longeveron also reported gains, reflecting continued investor confidence in their research and development efforts, despite no new corporate updates.

[object Object]
Preview
7.5
11-20Newsfilter
Molecular Instruments and Standard BioTools Team Up to Enhance Imaging Mass Cytometry with Amplified Multi-Omic Readouts

  • Collaboration Announcement: Molecular Instruments and Standard BioTools have partnered to enhance Imaging Mass Cytometry (IMC) workflows using HCR imaging technologies, allowing for improved protein imaging with any primary antibody.

  • Technological Integration: The collaboration combines HCR Gold for RNA and protein imaging with the Hyperion Imaging System, enabling amplified detection of low-abundance markers and enhancing the flexibility and sensitivity of spatial biology workflows.

  • Unified Multi-Omic Analysis: The integration aims to create a platform for simultaneous high-fidelity analysis of RNA and protein targets, facilitating deeper insights into complex tissues through a single workflow.

  • Future Development: Joint development activities are currently in progress, with opportunities for early access available to interested collaborators, aiming to accelerate the transition from discovery to clinical applications.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Standard BioTools Inc (LAB) stock price today?

The current price of LAB is 1.44 USD — it has increased 0 % in the last trading day.

arrow icon

What is Standard BioTools Inc (LAB)'s business?

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

arrow icon

What is the price predicton of LAB Stock?

Wall Street analysts forecast LAB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Standard BioTools Inc (LAB)'s revenue for the last quarter?

Standard BioTools Inc revenue for the last quarter amounts to 19.55M USD, decreased -56.52 % YoY.

arrow icon

What is Standard BioTools Inc (LAB)'s earnings per share (EPS) for the last quarter?

Standard BioTools Inc. EPS for the last quarter amounts to -0.09 USD, increased 28.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Standard BioTools Inc (LAB)'s fundamentals?

The market is revising Downward the revenue expectations for Standard BioTools Inc. (LAB) for FY2025, with the revenue forecasts being adjusted by -6.83% over the past three months. During the same period, the stock price has changed by 10.77%.
arrow icon

How many employees does Standard BioTools Inc (LAB). have?

Standard BioTools Inc (LAB) has 818 emplpoyees as of December 05 2025.

arrow icon

What is Standard BioTools Inc (LAB) market cap?

Today LAB has the market capitalization of 553.77M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free